Добавил:
ivanov666
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Хронический кардиоренальный синдром
.pdf
260. Pitt B. Neurohumoral eects of aliskiren in patients
with symptomatic heart failure patients receiving a
mineralcortocoid receptor antagonist: the Aliskiren
Observation of Heart Failure Treatment study / B. Pitt // Eur
J Heart Fail. – 2011. – Vol. 13, N. 7. – P. 755–764.
261. Poetzi G. Concomitant renal and hepatic dysfunctions in
chronic heart failure: clinical implications and prognostic
signicance / G. Poetzi // Eur. J. Intern. Med. – 2013. –
Vol. 24, N. 2. – P. 177–182.
262. Poletti R. Prognostic value of plasma rennin activity in heart
failure patients with chronic kidney disease / R. Poletti // J Int
Cardiol. – 2013. – Vol. 167, N. 3. – P. 711–715.
263. Proctor G. Regulation of renal fatty acid and cholesterol
metabolism, inammation and brosis in Akita and OVE26
mice with type I diabetes / G. Proctor // Diabetes. – 2006. –
Vol. 55, N. 9. – P. 2502–2509.
264. Rahman M. Cardiovascular outcomes in high–risk
hypertensive patients stratied by baseline glomerular
ltration rate / M. Rahman // Ann Untern Med. – 2006. –
Vol. 144, N. 3. – P. 172–180.
265. Raq K. Pathophysiological role of aldosterone and
mineralcortocoid receptor in the kidney / K. Raq // J
Pharmacol Sci. – 2011. – Vol. 115, N. 1. – P. 1–7.
266. Rehsia N.S. Mechanisms of benecial eects of beta–
adrenoceptor antagonists in congestive heart failure /
N. S. Rehsia, N.S. Dhala // Exp Clin Cardiol. – 2010. –
Vol. 15, N. 4. – P. e86–e95.
267. Reilly T. Vasopressine antagonist: pharmacotherapy for
treatment of heart failure / T. Reilly, M.R. Schork // Ann
Pharmacother. – 2010. – Vol. 44, N. 4. – P. 680–687.
268. Remes J. Neuroendocrine activity in untreated heart failure /
J. Rеmes, I. Tikkanen, F. Fyhrquust // Brit Heart J. – 1991. –
Vol. 65, N. 2. – P. 249–255.
269. Rocha R. Aldosterone induces a vascular inammatory
phenotype in the rat heart / R. Rocha // Am J Physiol Heart. –
231
2002. – Vol. 283, N. 5. – P. H1802–H1813.
270. Rosas–Arellano M.P. c–Fos induction in spinal cord neurons
aer renal arterial or venous occlusion / M.P. Rosas–Arellano
// Am. J. Physiol. Regul. – 1999. – Vol. 276, N. 1. – P. R120–
R127.
271. Ross E.H. Congestive renal failure : the pathophysiology and
treatment of renal venous hypertension // J Card Fail. – 2012. –
Vol. 18, N. 12. – P. 930–938.
272. Rossi G. Aldosterone as cardiovascular risk factor / G. Rossi,
M. Boscaro, V. Ronconi // Endocronol Metab. – 2005. – Vol.
16, N. 3. – P. 104–107.
273. Ronco C. Cardio–renal syndromes: report from the consensus
conference of Acute Dialysis Quality Initiative / C. Ronco //
Eur Heart J. – 2010. – Vol. 31, N. 6. – P. 703–711.
274. Ronco C. Cardio–renal syndrome type 1: pathophysiological
crosstalk leading to combined heart and kidney dysfunction
in the setting of acutely decompensated heart failure /
C. Ronco, M. Cicoira, P.A. McCullough // J Am Coll Cardiol. –
2012. – Vol. 60, N. 12. – P. 1031–1042.
275. Ruilope L.M. Renal function and intensive lowering of blood
pressure in the hypertensive subjects of the Hypertension
Optimal Treatment (HOT) Study / L. Ruilope // J Am Soc
Nephrol. – 2001. – Vol. 12, N. 2. – P. 218–225.
276. Sahai A. Mechanism of chronic hypoxia–induced renal cell
growth / A. Sahai, C. Me, R.W. Shrier // Kidney Int. – 1999. –
Vol. 56, N. 4. – P. 1277–1281.
277. Sakoda M. Aliskiren inhibits intracellular angiotensin II
levels without aecting (pro0renin receptor signals in human
podocytes / M. Sakoda // Am J Hypertens. – 2010. – Vol. 23,
N. 5. – P. 575–580.
278. Sakoda M. Podocytes as a target of prorenin in diabetes /
M. Sakoda, H. Itoh, A. Ichihara // Curr Diabetes Rev. – 2011. –
Vol. 7, N. 1. – P. 17–21.
279. Shibahara H. Cardiorenal protective eects of the oral
uremic toxin adsorbent AST–120 in chronic heart disease
232
patients with moderate CKD / H. Shibahara, N. Shibahara //
J Nephrol. – 2010. – Vol. 23, N. 5. – P. 535–540.
280. Shibata S. Podocyte as a target for aldosterone: Roles of
oxidative stress and Sgk 1 / S. Shibata // Hypertension. –
2007. – Vol. 49, N. 2. – P. 355–364.
281. Schindler C. Role of vasodilatator peptide angiotensin (1–7)
in the cardiovascular drug therapy / C. Schindler // Vascular
Health Risk Management. – 2007. – Vol. 3, N. 1. – P. 125–137.
282. Shah A. Endothelial function and arterial compliance are
not impaired in patients with heart failure 0f non–ischemic
origin / A. Shah, E. Gkaliagkousi, J.M. Ritter // J Card Fail. –
2010. – Vol. 16, N. 2. – P. 114–120.
283. Shaq M.M. Blocking aldosterone in heart failure /
M. M. Shaq, A.B. Miller // er Adv Cardiovasc Dis. – 2009. –
Vol. 3, N. 5. – P. 379–385.
284. Shankar S.S. Loop diuretics: from the Na–K–2Cl transporter
to clinical use / S.S. Shankar, D.C. Brater // Am J Physiol
Renal. – 2003. – Vol. 284, N. 1. – P. F11–F21.
285. Shepherd J. Treating to New Target Investigators. Eect of
intensive lipid lowering with atorvastatin on renal function
in patients with coronary heart disease: the Treating to New
Target (TNT) study / J. Shepherd // Clin J Am Soc Nephrol.
– 2007. – Vol. 2, N. 6. – P. 1131–1139.
286. Shimizu H. Indoxyl sulfate upregulated renal expression of
MCP–1 via production of ROS and activation of NF–kB, p53,
ERK and JNK in proximal tubular cells / H. Shimizu // Life
Sci. – 2012. – Vol. 90, N. 13–14. – P. 525–530.
287. Siddiqi L. Aliskiren reduces sympathetic nerve activity and
blood pressure in chronic kidney disease patients / L. Siddiqi,
P.L. Oey, P.J. Blankestijn // Nephrol Dial Transplant. – 2011. –
Vol. 26, N. 9. – P. 2930–2934.
288. Siddiqi L. Sympathetic activity in chronic kidney disease
is related to le ventricular mass despite antihypertensive
treatment / L. Siddiqi // Nephrol Dial Transplant. – 2010. –
Vol. 20, N. 6. – P. 1048–1058.
233
289. Sidik N.P. Eect of aliskiren in patients with heart failure
according to background dose of ACE inhibitor: a
retrospective analysis of Aliskiren Observation of Heart
Failure Treatment (ALOFT) trial / N.P. Sidik // Cardiovasc
Drug er. – 2011. – Vol. 25, N. 4. – P. 315–321.
290. Silveberg D.S. e role of erythropoiesis stimulating agents
and intravenous iron in the cardiorenal anemia syndrome //
Heart Fail Rev. – 2011. – Vol. 16, N. 16. – P. 609–614.
291. Siragy H.M. Renal (pro)renin receptor upregulation in
diabetic rats through enhances angiotensin AT1–receptor
and NADPH oxydase activity / H.M. Siragy, J. Huang // Exp
Physiol. – 2008. – Vol. 93, N. 5. – P. 709–714.
292. Smith G.L. Renal impairment and outcomes in heart failure.
Systemic review and meta–analysis / G.L. Smith // J Am Coll
Cardiol. – 2006. – Vol. 47, N. 10. – P. 1987–1996.
293. Sodhi C.P. Osteopontin mediates hypoxia–induced
proliferation of cultured mesangial cells: role of PKC and p38
MAPK / C.P. Sodhi, D. Battle, A. Sahai // Kidney Int . – 2000. –
Vol. 58, N. 2. – P. 691–700.
294. Solomon S.D. Eect of direct renin inhibitor aliskiren on le
ventricular remodeling following myocardial infarction with
systolic dysfunction / S.D. Solomon // Eur Heart J. – 2011. –
Vol. 32, N. 10. – P. 1227–1234.
295. Sonalker P.A. Norepinephrine via beta–adrenoceptors regulates
bumetanide–sensitive cotransporter type 1 expression in the
thick ascending limb cells / P.A. Sonalker, E.K. Jackson //
Hypertension. – 2007. – Vol. 49, N. 6. – P. 1351–1357.
296. Sonalker P.A. Chronic noradrenaline increases renal
expression of NHE3, NBC–1, BSC–1 and aquaporin–2 /
P.A. Sonalker, S.P. Tofovic, S.I Bastacki // Clin Exp Pharmacol
Physiol. – 2008. – Vol. 35, N. 5–6.– P. 594–600.
297. Song Y.R. Activation of hypoxia–inducible factor attenuates
renal injury in rat remnant kidney / Y.R. Song // Nephrol
Dial Transplant. – 2010. – Vol. 25, N. 1. – P. 77–85.
298. Soni S.S. Cardio–renal syndrome type 5: epidemiology,
234
pathophysiology and treatment / S.S. Soni // Semin Nephrol. –
2012. – Vol. 32, N.1. – P. 49–56.
299. Schmidt–Ott K.M. Dual action of neutrophil gelatinase–
associated lipocain / K.M. Schmidt–Ott // J Am Soc Nephrol. –
2007. – Vol. 18, N. 2. – P. 407–413.
300. Stanojevic D. Prevalence of renal dysfunction and its inuence
on functional capacity in elderly patients with stable chronic
heart failure / D. Stanojevic // Voinosanit Preql. – 2012. –
Vol. 69, N. 10. – P. 840–845.
301. Steenhard B.M. Deletion of von Hippel–Lindau in glomerular
podocytes results in glomerular basement membrane
thickening , ectopic subepithelial deposition of collagen IV,
expression of neuroglobin and proteinuria / B.M. Steenhard
// Am J Pathol. – 2010. – Vol. 177, N. 1. – P. 84–96.
302. Sun S. Hypoxia–inducible factor–alpha induces Twist
expression in tubular epithelial cells subjected hypoxia,
leading to epithelial–mesenchymal transition / S. Sun //
Kidney Int. – 2009. – Vol. 75, N. 12. – P. 1278–1287.
303. Takahashi H. Inhibition of nephropathy developed in
diabetes by (pro)renin receptor blockade / H. Takahashi // J
Am Soc Nephrol. – 2007. – Vol. 18, N. 7. – P. 2054–2061.
304. Tamirisa K.P. Spironolactone–induced renal insuciency and
hyperkaliemia in patients with heart failure / K.P. Tamirisa,
K.D. Aaronson, T.M. Koelling // Am Heart J. – 2004. –
Vol. 148, N. 6. – P. 971–978.
305. Tanaka M. Eects of various diuretics on cardiac function
in rats with heart failure / M. Tanaka // Yakugaku Zasshi. –
2009. – Vol. 129, N. 7. – P. 871–879.
306. Tanaka M. Deterioration of renal dysfunction by chronic
heart failure is associated with congestion and oxidative
stress in the tubular interstitium / M. Tanaka // Intern Med. –
2011. – Vol. 50, N. 23. – P. 2877–2887.
307. Teerlink T. ADMA metabolism and clearance // Vasc Med. –
2005. – Vol. 10 [suppl 1]. – P. S73–S81.
308. Tinucci T. Mild chronic insuciency induces sympathetic
235
overactivity / T. Tinucci // J Hum Hypertens. – 2001. –
Vol. 15, N. 6. – P. 401–406.
309. Tobe S.W. Cardiovascular and renal outcomes with telmisartan,
ramipril or boths in people with high renal risk / S.W. Tobe //
Circulation. – 2011. – Vol. 123, N. 10. – P. 1098–1107.
310. Triposkiadis F. e sympathetic nervous system in heart
failure: physiology, pathophysiology and clinical implications
/ F. Triposkiadis // Am J Coll Cardiol. – 2009. – Vol. 45,
N. 19. – P. 1747–1762.
311. Tumur Z. Indoxyl sulfate upregulates expression of ICAM–
1 and MCP–1 by oxidative stress–induced NF–kappa B
activation / Z. Tumur // Am J Nephrol. – 2010. – Vol. 31,
N. 5. – P. 435–441.
312. Udelson J.E. A multicenter randomized, double–blind,
placebo–controlled study of tolvaptan monotherapy
compared to furosemide and the combination of tolvaptan
and furosemide in patients with heart failure and systolic
dysfunction / J.E. Udelson // J Cardiol Fail. – 2011. – Vol. 17,
N. 12. – P. 973–981.
313. Vaidyanathan S. Pharmacokinetics of oral direct renin
inhibitor aliskiren alone and in combination with irbesartan in
renal impairment / S. Vaidyanathan // Clin pharmacokinet. –
2007. – Vol. 46, N. 8. – P. 661–675.
314. Vaidyanathan S. Clinical pharmacokinetics and pharmacodynamics of aliskiren / Clin pharmacokinet. – 2008. –
Vol. 47, N. 8. – P. 515–531.
315. Vallon V. Adenosine and kidney function: potential
implications in patients with heart failure / V. Vallon,
C. Miracle, S. omson // Eur J Heart Fail. – 2008. – Vol. 10,
N. 2. – P. 176–187.
316. Van De Wal R.M. High prevalence of microalbuminuria in
chronic heart failure / M.M. van De Wal // J Card Fail. –
2005. – Vol. 11, N. 8. – P. 602–606.
317. Vanholder R. Chronic kidney disease as cause of cardiovascular
morbidity and mortality / R. Vanholder // Nephrol Dial
Transplant. – 2005. – Vol. 20, N. 6. – P. 1048–1058.
236
318. Van Timmeren M.M. Tubular kidney injury molecule–1
(KIM–1) in human renal disease / M.M. van Timmeren //
J Pathol. – 2007. – Vol. 212, N. 2. – P. 209–217.
319. Vanholder R. Chronic kidney disease as cause of cardiovascular
morbidity and mortality / R. Vanholder // Nephrol Dial
Transplant. – 2005. – Vol. 20, N. 6. – P. 1048–1058.
320. Vardeny O. Inuence of baseline and worsening renal
function on ecacy of spironolactone in patients with
severe heart failure: insights from Randomized Aldactone
Evaluation Study / O. Vardeny // J Am Coll Cardiol. – 2012. –
Vol. 60, N. 20. – P. 2082–2089.
321. Vasco M.R. Furosemide absorption altered in the
decompensated heart failure / M.R. Vasco // Ann Intern
Med. – 1985. – Vol. 102, N. 3. – P. 314–318.
322. Veeraveedu P.T. Comparative eects of torasemide and
furosemide in rats with heart failure / P.T. Veeraveedu //
Biochem Pharmacol. – 2008. – Vol. 75, N. 3. – P. 649–659.
323. Verhulst A. Inhibitors of HMG–CoA reductase reduce
receptor–mediated endocytoses in human kidney proximal
cells / A. Verhulst, P.C. D’Haese, M.E. De Broe // J Am Soc
Nephrol. – 2004. – Vol. 15, N. 9. – P. 2249–2257.
324. Veron D. Overexpression of VEGF–A in podocytes of adult
mice causes glomerular disease / D. Veron // Kidney Int. –
2010. – Vol. 77, N. 11. – P. 989–999.
325. Volpe M. Blood levels of erythropoietin in congestive heart
failure and correlation with clinical, hemodynamic and
hormonal proles / M. Volpe, C. Tritto, U Testa // Am J
Cardiol. – 1994. – Vol. 74, N. 5. – P. 468–473.
326. Voors A.A. Eects of adenosine A1 receptor antagonist
rolofylline on renal function in patients with acute heart
failure and renal dysfunction: result from PROTECT /
A.A. Voors // J Am Coll Cardiol. – 2011. – Vol. 57, N. 19. –
P. 1899–1907.
327. Wali P.K. Ecacy and safety of cardilol treatment on
heart failure in chronic kidney disease: a meta–analysis of
237
randomized trials / P.K. Wali // Circ Heart Fail. – 2011. –
Vol. 4, N. 1. – P. 18–36.
328. Wang M.C. Stepwise increase in arterial stiness
corresponding with the stages of chronic kidney disease /
M.C. Wang, W.C. Tsai, J.J. Huang // Am J Kidney Dis. – 2005. –
Vol. 45, N. 3. – P. 494–501.
329. Wang Z. Regulation of renal lipid metabolism, lipid
accumulation and glomerulosclerosis in FVB db/db mice
with type 2 diabetes / Z. Wang // Diabetes. – 2005. – Vol. 54,
N. 11. – P. 2328–2335.
330. Wang Z. Hypoxia–inducible factor–1α contributes to the
probrotic action of angiotensin II in renal medullary
interstitial cells / Z. Wang // Kidney Int. – 2011. – Vol. 79,
N. 3. – P. 300–310.
331. Weiner D.E. Eects of anemia and le ventricular hypertrophy
on cardiovascular disease in patients with chronic kidney
disease / D.E. Weiner // J Am Soc Nephrol. – 2005. – Vol. 16,
N. 6. – P. 1803–1810.
332. Weir M. Antihypertensive ecacy, safety and tolerability
of the oral direct renin inhibitor aliskiren in patients with
hypertension: A pooled analysis / M. Weir // J Am Soc
Hypertens. – 2007. – Vol. 1, N. 4. – P. 264–277.
333. Wong J. e clinical use of angiotensin converting enzyme
inhibitors / J. Wong, R.A. Patel, P.R. Kowey // Progr
Cardiovasc Dis. – 2004. – Vol. 47, N. 2. – P. 116–130.
334. Wu Y. Eects of rosuvastatin and atorvastatin on renal function
/ Y. Wu // Circ J. – 2012. – Vol. 76, N. 5. – P. 1258–1266.
335. Yoshida H. Glomerular hyperltration and sclerosis in
chronic heart failure / H. Yoshida // J Am Soc Nephrol. –
1995. – Vol. 3, N. 6. – P. 689 (Abstract).
336. Yoshida H. Mesangiolytic glomerulopathy in severe
congestive heart failure / H. Yoshida // Kidney Int. – 1998. –
Vol. 53, N. 4. – P. 880–891.
337. Zannad F. EMPHASIS–HF Study Group Eplerenone in
patients with systolic heart failure and mild symptoms /
238
F. Zannad // N Engl J Med. – 2011. – Vol. 364, N.1. –
P. 11–21.
338. Zeman M. N–3 fatty acid supplementation decreased plasma
homocysteine in diabetic dyslipidaemia trated with statin–
brate combination / M. Zeman // J Nutr Biochem. – 2006. –
Vol. 17, N. 6. – P. 357–384.
339. Zhang J. Receptor–dependent prorenin activation and
induction of PAI–1 expression in vascular smooth muscle
cells / J. Zhang // Am J Physiol Endocrinol Metab. – 2008. –
Vol. 295, N. 4. – P. E810–E819.
340. Zheng H. Increased renal ENaC subunits and sodium
retention in rats with chronic heart failure / H. Zheng // Am
J Physiol Renal. – 2011. – Vol. 300, N. 3. – P. F641–F649.
341. Zhou Q. Acute and acute–on–chronic kidney injury of
patients with decompensated heart failure: impact on
outcomes / Q. Zhou // BMC Nephrol. – 2012. – Vol. 13,
N. 1. – P. 51–60.
342. Zhuo J.L. New insights and perspectives on intrarenal
renin–angiotensin system: focua on intracrine/intracellular
angiotensin II / J.L. Zhuo, X.C. Li // Peptides.– 2011. – Vol.
32, N. 7. – P. 1551–1565.
343. Zoccali C. Plasma concentration of asymmetric
dimethylarginine and mortality in patients with end–stage
renal disease: a prospective study / C. Zoccali // Lancet. –
2001. – Vol. 358, N. 9299. – P. 2113–2117.
344. Zoccali C. Asymmetrical dimethylarginine, C–reactive
protein and caroid intima–media thickness in end–stage
renal disease / C. Zoccali // J Am Soc Nephrol. – 2002. –
Vol. 13, N. 2. – P. 490–496.
345. Zoccali M. Le ventricular hypertrophy, cardiac remodeling
and asymmetric dimethylarginine (ADMA) in hemodialysis
patients / C. Zoccali // Kidney Int. – 2002. – Vol. 62, N. 1. –
P. 339–345.
239
Список сокращений
АГ – артериальная гипертония
АД – артериальное давление
АДМА – асимметричный диметиларгинин
Анг II – ангиотензин II
АРА – антагонисты рецепторов ангиотензина
АРП – активность ренина плазмы крови
АПФ – ангиотензин–I–превращающий фермент
ГБМ – гломерулярная базальная мембрана
ГЛЖ – гипертрофия левого желудочка
ГМГ–КоА–
редуктаза
ДГК – доксагексаеновая кислота
ИБС – ишемическая болезнь сердца
ЛЖ – левый желудочек
ЛПВП – липопротеиды высокой плотности
ЛПНП – липопротеиды низкой плотности
ЛПОНП – липопротеиды очень низкой плотности
МК–рецеп-
торы
МНП – мозговой натрийуретический пептид
ОПН – острая почечная недостаточность
ОСН – острая сердечная недостаточность
ПЖ – правый желудочек
ПК – проксимальный каналец
ПНЖК – полиненасыщенные жирные кислоты
– 3–гидрокси–3–метилглутарил–коэнзим
А–редуктаза
– минералкортикоидные рецепторы
240
Соседние файлы в предмете [НЕСОРТИРОВАННОЕ]